Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Human Papillomavirus Selected Properties and Related Cervical Cancer Prevention Issues

Author(s): Saule Balmagambetova*, Andrea Tinelli, Ospan A. Mynbaev, Arip Koyshybaev, Olzhas Urazayev, Nurgul Kereyeva and Elnara Ismagulova

Volume 26, Issue 18, 2020

Page: [2073 - 2086] Pages: 14

DOI: 10.2174/1381612826666200422094205

Price: $65

Abstract

High-risk human papillomavirus strains are widely known to be the causative agents responsible for cervical cancer development. Aggregated damage caused by papillomaviruses solely is estimated in at least 5% of all malignancies of the human body and 16% in cancers that affect the female genital area. Enhanced understanding of the complex issue on how the high extent of carcinogenicity is eventually formed due to the infection by the Papoviridae family would contribute to enhancing current prevention strategies not only towards cervical cancer, but also other HPV associated cancers. This review article is aimed at presenting the key points in two directions: the current cervical cancer prevention and related aspects of HPV behavior. Virtually all applied technologies related to HPV diagnostics and screening programs, such as HPV tests, colposcopy-based tests (VIA/VILI), conventional and liquid-based cytology, currently available are presented. Issues of availability, advantages, and drawbacks of the screening programs, as well as vaccination strategies, are also reviewed in the article based on the analyzed sources. The current point of view regarding HPV is discussed with emphasis on the most problematic aspect of the HPV family concerning the observed increasing number of highly carcinogenic types. Present trends in HPV infection diagnostics throughout the human fluids and tissues are also reported, including the latest novelties in this field, such as HPV assay/self-sample device combinations. Besides, a brief outline of the related prevention issues in Kazakhstan, the leading country of Central Asia, is presented. Kazakhstan, as one of the post-soviet middle-income countries, may serve as an example of the current situation in those terrains, concerning the implementation of globally accepted cervical cancer prevention strategies. Along with positive achievements, such as the development of a nationwide screening program, a range of drawbacks is also analyzed and discussed.

Keywords: Human papillomavirus, cervical cancer, screening, vaccination, incidence, Kazakhstan.

Next »
[1]
World Health Organization. Geneva: World Health Organization; Global Health Observatory. Available from: . who.int/gho/database/en/
[2]
Varghese C, Carlos MC, Shin HR. Cancer burden and control in the Western Pacific region: challenges and opportunities. Ann Glob Health 2014; 80(5): 358-69.
[http://dx.doi.org/10.1016/j.aogh.2014.09.015] [PMID: 25512151]
[3]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[4]
Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet 2017; 389(10071): 847-60.
[http://dx.doi.org/10.1016/S0140-6736(16)31392-7] [PMID: 27814965]
[5]
Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) Human Papillomavirus and Related Diseases in the World Summary Report 17 June 2019.Available from: . http://www.hpvcentre.net/statistics/ reports/
[6]
Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev 2018; 19(2): 319-24.
[PMID: 29479954]
[7]
Rogovskaya SI, Shabalova IP, Mikheeva IV, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine 2013; 31(7): H46-58.
[http://dx.doi.org/10.1016/j.vaccine.2013.06.043] [PMID: 24332297]
[8]
Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine 2013; 31(S7): H32-45.
[http://dx.doi.org/10.1016/j.vaccine.2013.02.071] [PMID: 24332296]
[9]
Evantash E. The critical importance of HPV co-testing for cervical cancer screening Special report Available from: https://www.mlo-online.com/diagnostics/assays/article/13009414/
[10]
Centers for Disease Control and Prevention Basic Information about Cervical Cancer Available from: https://www.cdc.gov/ cancer/cervical/index.htm
[11]
Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32(1): 26-32.
[http://dx.doi.org/10.1016/j.vaccine.2013.10.085] [PMID: 24211166]
[12]
McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta 2008; 1782(3): 127-50.
[http://dx.doi.org/10.1016/j.bbadis.2007.12.005] [PMID: 18201576]
[13]
Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014; 15(3): 266-82.
[http://dx.doi.org/10.1016/j.chom.2014.02.011] [PMID: 24629334]
[14]
zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384(2): 260-5.
[http://dx.doi.org/10.1016/j.virol.2008.11.046] [PMID: 19135222]
[15]
Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26(S10): K29-41.
[http://dx.doi.org/10.1016/j.vaccine.2008.06.019] [PMID: 18847555]
[16]
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9.
[http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F] [PMID: 10451482]
[17]
Herrera-Goepfert R, Vela-Chávez T, Carrillo-García A, et al. High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women. BMC Cancer 2013; 13: 445.
[http://dx.doi.org/10.1186/1471-2407-13-445] [PMID: 24083491]
[18]
Cheng YW, Lin FC, Chen CY, Hsu NY. Environmental exposure and HPV infection may act synergistically to induce lung tumorigenesis in nonsmokers. Oncotarget 2016; 7(15): 19850-62.
[http://dx.doi.org/10.18632/oncotarget.7628] [PMID: 26918347]
[19]
Guo L, Liu S, Zhang S, et al. Human papillomavirus infection as a prognostic marker for lung adenocarcinoma: a systematic review and meta-analysis. Oncotarget 2017; 8(21): 34507-15.
[http://dx.doi.org/10.18632/oncotarget.15671] [PMID: 28427144]
[20]
Cardona AF, Ruiz-Patiño A, Ricaurte L, et al. Human papillomavirus infection and lung cancer. In: Saxena SK.. Infectious Diseases Current Perspectives in Human Papillomavirus. London: IntechOpen 2018; 2:: pp. 47-67.
[21]
Muñoz N, Bosch FX, de Sanjosé S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-27.
[http://dx.doi.org/10.1056/NEJMoa021641] [PMID: 12571259]
[22]
Bouvard V, Baan R, Straif K, et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009; 10(4): 321-2.
[http://dx.doi.org/10.1016/S1470-2045(09)70096-8] [PMID: 19350698]
[23]
Menzo S, Monachetti A, Trozzi C, et al. Identification of six putative novel human papillomaviruses (HPV) and characterization of candidate HPV type 87. J Virol 2001; 75(23): 11913-9.
[http://dx.doi.org/10.1128/JVI.75.23.11913-11919.2001] [PMID: 11689676]
[24]
Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401(1): 70-9.
[http://dx.doi.org/10.1016/j.virol.2010.02.002] [PMID: 20206957]
[25]
Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
[http://dx.doi.org/10.1186/1750-9378-4-8] [PMID: 19486508]
[26]
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; Biological agents Volume 100 B A review of human carcinogens IARC Monogr Eval Carcinog Risks Hum 2012; 100(Pt B): 1-441.Available from: . https://www.ncbi.nlm.nih.gov/ pubmed/23189750
[27]
Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013; 445(1-2): 224-31.
[http://dx.doi.org/10.1016/j.virol.2013.07.015] [PMID: 23928291]
[28]
Halec G, Alemany L, Lloveras B, et al. Retrospective International Survey and HPV Time Trends Study Group; Retrospective International Survey and HPV Time Trends Study Group. . Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 2014; 234(4): 441-51.
[http://dx.doi.org/10.1002/path.4405] [PMID: 25043390]
[29]
Balmagambetova SK, Tinelli A, Urazayev ON, et al. HPV types distribution in general female population and in women diagnosed with cervical cancer across western Kazakhstan. Asian Pac J Cancer Prev 2019; 20(4): 1089-96.
[http://dx.doi.org/10.31557/APJCP.2019.20.4.1089] [PMID: 31030478]
[30]
Kim NR, Kang M, Lee SP, et al. Uncommon and rare human papillomavirus genotypes relating to cervical carcinomas. Korean J Pathol 2014; 48(1): 43-9.
[http://dx.doi.org/10.4132/KoreanJPathol.2014.48.1.43] [PMID: 24627694]
[31]
Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol 2014; 234(4): 431-5.
[http://dx.doi.org/10.1002/path.4424] [PMID: 25124771]
[32]
Du PL, Wu KS, Fang JY, et al. Cervical cancer mortality trends in China, 1991-2013, and predictions for the future. Asian Pac J Cancer Prev 2015; 16(15): 6391-6.
[http://dx.doi.org/10.7314/APJCP.2015.16.15.6391] [PMID: 26434848]
[33]
Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92(5): 891-4.
[http://dx.doi.org/10.1038/sj.bjc.6602436] [PMID: 15756259]
[34]
Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360(9328): 228-9.
[http://dx.doi.org/10.1016/S0140-6736(02)09463-1] [PMID: 12133661]
[35]
Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106(3): 396-403.
[http://dx.doi.org/10.1002/ijc.11222] [PMID: 12845680]
[36]
Deng T, Feng Y, Zheng J, Huang Q, Liu J. Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery. J Gynecol Oncol 2015; 26(2): 111-7.
[http://dx.doi.org/10.3802/jgo.2015.26.2.111] [PMID: 25872892]
[37]
Chen AA, Heideman DA, Boon D, et al. Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology 2014; 448: 356-62.
[http://dx.doi.org/10.1016/j.virol.2013.10.033] [PMID: 24314666]
[38]
Chen AA, Heideman DA, Boon D, et al. IARC HPV Variant Study Group. Human papillomavirus 45 genetic variation and cervical cancer risk worldwide. J Virol 2014; 88(8): 4514-21.
[http://dx.doi.org/10.1128/JVI.03534-13] [PMID: 24501412]
[39]
Cornet I, Gheit T, Iannacone MR, et al. IARC HPV Variant Study Group. HPV16 genetic variation and the development of cervical cancer worldwide. Br J Cancer 2013; 108(1): 240-4.
[http://dx.doi.org/10.1038/bjc.2012.508] [PMID: 23169278]
[40]
Boumba LMA, Assoumou SZ, Hilali L, Mambou JV, Moukassa D, Ennaji MM. Genetic variability in E6 and E7 oncogenes of human papillomavirus Type 16 from Congolese cervical cancer isolates. Infect Agent Cancer 2015; 10(15): 15.
[http://dx.doi.org/10.1186/s13027-015-0010-4] [PMID: 25991921]
[41]
Chen Z, de Freitas LB, Burk RD. Evolution and classification of oncogenic human papillomavirus types and variants associated with cervical cancer. Methods Mol Biol 2015; 1249: 3-26.
[http://dx.doi.org/10.1007/978-1-4939-2013-6_1] [PMID: 25348294]
[42]
Ramas V, Mirazo S, Bonilla S, Ruchansky D, Arbiza J. Analysis of human papillomavirus 16 E6, E7 genes and Long Control Region in cervical samples from Uruguayan women. Gene 2018; 654: 103-9.
[http://dx.doi.org/10.1016/j.gene.2018.02.023] [PMID: 29454092]
[43]
Lehoux M, D’Abramo CM, Archambault J. Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics 2009; 12(5-6): 268-80.
[http://dx.doi.org/10.1159/000214918] [PMID: 19684440]
[44]
MLO-online. The five FDA-approved HPV assays Available from: https://www.mlo-online.com/ the-five-fda-approved-hpv-assays.php
[45]
Lewis JS Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012; 6(S1): S75-82.
[http://dx.doi.org/10.1007/s12105-012-0369-0] [PMID: 22782226]
[46]
Venuti A, Paolini F. HPV detection methods in head and neck cancer. Head Neck Pathol 2012; 6(S1): S63-74.
[http://dx.doi.org/10.1007/s12105-012-0372-5] [PMID: 22782225]
[47]
Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344(15): 1125-31.
[http://dx.doi.org/10.1056/NEJM200104123441503] [PMID: 11297703]
[48]
Chai RC, Lambie D, Verma M, Punyadeera C. Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med 2015; 4(4): 596-607.
[http://dx.doi.org/10.1002/cam4.424] [PMID: 25644715]
[49]
Liang C, Marsit CJ, McClean MD, et al. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res 2012; 72(19): 5004-13.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3277] [PMID: 22991304]
[50]
Rampias T, Sasaki C, Psyrri A. Molecular mechanisms of HPV induced carcinogenesis in head and neck. Oral Oncol 2014; 50(5): 356-63.
[http://dx.doi.org/10.1016/j.oraloncology.2013.07.011] [PMID: 23953776]
[51]
Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL, Lewis JS Jr. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol 2011; 35(9): 1343-50.
[http://dx.doi.org/10.1097/PAS.0b013e318220e59d] [PMID: 21836494]
[52]
Schache AG, Liloglou T, Risk JM, et al. Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br J Cancer 2013; 108(6): 1332-9.
[http://dx.doi.org/10.1038/bjc.2013.63] [PMID: 23412100]
[53]
Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116(9): 2166-73.
[http://dx.doi.org/10.1002/cncr.25033] [PMID: 20186832]
[54]
Tinelli A, Guido M, Zizza A, et al. The mRNA-HPV test utilization in the follow up of HPV related cervical lesions. Curr Pharm Des 2013; 19(8): 1458-65.
[PMID: 23016779]
[55]
Boehmer G, Wang L, Iftner A, et al. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off. BMC Infect Dis 2014; 14: 674.
[http://dx.doi.org/10.1186/s12879-014-0674-1] [PMID: 25487281]
[56]
Boers A, Wang R, van Leeuwen RW, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics 2016; 8(29): 29.
[http://dx.doi.org/10.1186/s13148-016-0196-3] [PMID: 26962367]
[57]
Bowden SJ, Kalliala I, Veroniki AA, et al. The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: a systematic review and meta-analysis. EBioMedicine 2019; S2352-3964(19): 30728-5.
[58]
Yu-Hong W, Rui C, Ding L. A quantum dots and superparamagnetic nanoparticle-based method for the detection of HPV DNA. Nanoscale Res Lett 2011; 6(461): 461.
[http://dx.doi.org/10.1186/1556-276X-6-461] [PMID: 21774818]
[59]
Chen X, Bode AM, Dong Z, Cao Y. The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer. FASEB J 2016; 30(9): 3001-10.
[http://dx.doi.org/10.1096/fj.201600388R] [PMID: 27279361]
[60]
Arbyn M, Peeters E, Benoy I, et al. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. J Clin Virol 2018; 107: 52-6.
[http://dx.doi.org/10.1016/j.jcv.2018.08.006] [PMID: 30195193]
[61]
Arbyn M, Peeters E, Donders GGG, et al. ER248 VALHUDES: a protocol for VALidation of HUman papillomavirus assays and collection DEvices for HPV testing on Self-samples and urine samples. Conference: ESGO Annual Meeting Abstracts. In: Int J Gynecol Cancer. 29(S4): A196.2-196
[http://dx.doi.org/10.1136/ijgs-2019-ESGO.309]
[62]
de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13(6): 607-15.
[http://dx.doi.org/10.1016/S1470-2045(12)70137-7] [PMID: 22575588]
[63]
Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, Tabrizi SN. VACCINE study group. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine 2018; 36(23): 3221-30.
[http://dx.doi.org/10.1016/j.vaccine.2018.04.080] [PMID: 29724506]
[64]
USA CDC Press Release. 19 June 2013:. New study shows HPV vaccine helping lower HPV infection rates in teen girls Available from: https://www.cdc.gov/vaccines/news/press-rel/
[65]
Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res 2017; 43(10): 1597-601.
[http://dx.doi.org/10.1111/jog.13419] [PMID: 28707725]
[66]
Saslow D, Andrews KS, Manassaram-Baptiste D, et al. American Cancer Society Guideline Development Group. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin 2016; 66(5): 375-85.
[http://dx.doi.org/10.3322/caac.21355] [PMID: 27434803]
[67]
Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine 2014; 32(6): 733-9.
[http://dx.doi.org/10.1016/j.vaccine.2013.11.049] [PMID: 24291200]
[68]
Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol 2015; 22(8): 943-8.
[69]
Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine 2018; 36(32 Pt A): 4768-73.
[http://dx.doi.org/10.1016/j.vaccine.2017.12.079] [PMID: 29325819]
[70]
Toh ZQ, Kosasih J, Russell FM, Garland SM, Mulholland EK, Licciardi PV. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist 2019; 12: 1951-67.
[http://dx.doi.org/10.2147/IDR.S178381] [PMID: 31308715]
[71]
Riethmuller D, Jacquard AC, Lacau St Guily J, et al. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health 2015; 15(453): 453.
[http://dx.doi.org/10.1186/s12889-015-1779-1] [PMID: 25934423]
[72]
Saraiya M, Unger ER, Thompson TD, et al. HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015; 107(6): djv086
[http://dx.doi.org/10.1093/jnci/djv086] [PMID: 25925419]
[73]
Petrosky E, Bocchini JA Jr, Hariri S, et al. Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64(11): 300-4.
[PMID: 25811679]
[74]
Fishman J, Taylor L, Kooker P, Frank I. Parent and adolescent knowledge of HPV and subsequent vaccination. Pediatrics 2014; 134(4): e1049-56.
[http://dx.doi.org/10.1542/peds.2013-3454] [PMID: 25225141]
[75]
Huang Y, Lin M, Luo ZY, Li WY, Zhan XF, Yang LY. Low prevalence of HPV in male sexual partners of HR-HPV infected females and low concordance of viral types in couples in Eastern Guangdong. Asian Pac J Cancer Prev 2013; 14(3): 1755-60.
[http://dx.doi.org/10.7314/APJCP.2013.14.3.1755] [PMID: 23679269]
[76]
Freire MP, Pires D, Forjaz R, et al. Genital prevalence of HPV types and co-infection in men. Int Braz J Urol 2014; 40(1): 67-71.
[http://dx.doi.org/10.1590/S1677-5538.IBJU.2014.01.1010] [PMID: 24642151]
[77]
Nielson CM, Harris RB, Dunne EF, et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis 2007; 196(8): 1137-45.
[http://dx.doi.org/10.1086/521632] [PMID: 17955431]
[78]
Rodríguez-Álvarez MI, Gómez-Urquiza JL, Husein-El Ahmed H, Albendín-García L, Gómez-Salgado J, Cañadas-De la Fuente GA. Prevalence and risk factors of human papillomavirus in male patients: A systematic review and meta-analysis. Int J Environ Res Public Health 2018; 15(10): 2210.
[http://dx.doi.org/10.3390/ijerph15102210] [PMID: 30309014]
[79]
Hebnes JB, Olesen TB, Duun-Henriksen AK, Munk C, Norrild B, Kjaer SK. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med 2014; 11(11): 2630-44.
[http://dx.doi.org/10.1111/jsm.12652] [PMID: 25088239]
[80]
Tsikis S, Hoefer L, Bethimoutis G, et al. Risk factors, prevalence, and site concordance of human papillomavirus in high-risk Greek men. Eur J Cancer Prev 2018; 27(5): 514-20.
[http://dx.doi.org/10.1097/CEJ.0000000000000366] [PMID: 28394804]
[81]
Cai T. HPV Vaccination in Males: Another Step Forward. EBioMedicine 2015; 2(10): 1300-1.
[http://dx.doi.org/10.1016/j.ebiom.2015.09.039] [PMID: 26629518]
[82]
Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother 2014; 10(7): 2109-11.
[http://dx.doi.org/10.4161/hv.29137] [PMID: 25424825]
[83]
Markowitz LE, Gee J, Chesson H, Stokley S. Ten years of human papillomavirus vaccination in the United States. Acad Pediatr 2018; 18(2S): S3-S10.
[http://dx.doi.org/10.1016/j.acap.2017.09.014] [PMID: 29502635]
[84]
Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016; 13(2): 119-32.
[http://dx.doi.org/10.1038/nrclinonc.2015.146] [PMID: 26323382]
[85]
Centers for Diseases Control and Prevention.; Meites E, Szilagyi PG, Chesson HW, Unger ER, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices MMWR 2019; 68(32): 698-702.Available from: . https://www.cdc.gov/ mmwr/volumes/ 68/wr/ mm6832a3.htm
[86]
Centers for Diseases Control and Prevention. National Center for Immunization and Respiratory Diseases. Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2019.CDC Available from: https://www.cdc.gov/vaccines/ schedules/hcp/imz/adult-shell.html
[87]
Brotherton JML. Impact of HPV vaccination: Achievements and future challenges. Papillomavirus Res 2019; 7: 138-40.
[http://dx.doi.org/10.1016/j.pvr.2019.04.004] [PMID: 30978413]
[88]
Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132(10): 810-9.
[http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00009] [PMID: 10819705]
[89]
Singh VB, Gupta N, Nijhawan R, Srinivasan R, Suri V, Rajwanshi A. Liquid-based cytology versus conventional cytology for evaluation of cervical Pap smears: experience from the first 1000 split samples. Indian J Pathol Microbiol 2015; 58(1): 17-21.
[http://dx.doi.org/10.4103/0377-4929.151157] [PMID: 25673585]
[90]
Pan QJ, Hu SY, Zhang X, et al. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. Cancer Cytopathol 2013; 121(9): 473-82.
[http://dx.doi.org/10.1002/cncy.21297] [PMID: 23907807]
[91]
Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102(19): 1478-88.
[http://dx.doi.org/10.1093/jnci/djq356] [PMID: 20841605]
[92]
Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006; 24(S3): 71-7.
[http://dx.doi.org/10.1016/j.vaccine.2006.05.121] [PMID: 16950020]
[93]
Bucchi L, Baldacchini F, Mancini S, et al. Emilia-Romagna Region Workgroup for Cervical Screening Evaluation. Estimating the impact of an organised screening programme on cervical cancer incidence: A 26-year study from northern Italy. Int J Cancer 2019; 144(5): 1017-26.
[PMID: 30120770]
[94]
Kjær SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 2014; 25(2): 179-89.
[http://dx.doi.org/10.1007/s10552-013-0320-z] [PMID: 24242002]
[95]
C Kitchener H, Canfell K, Gilham C, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 2014; 18(23): 1-196.
[http://dx.doi.org/10.3310/hta18230] [PMID: 24762804]
[96]
Jentschke M, Hillemanns P. Systematic comparison of different meta-analyses, systematic reviews and HTA reports in Cervical Cancer screening based on cytology or HPV test. Geburtshilfe Frauenheilkd 2016; 76(10): 1081-5.
[http://dx.doi.org/10.1055/s-0042-112457] [PMID: 27761029]
[97]
Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 2015; 125(2): 330-7.
[http://dx.doi.org/10.1097/AOG.0000000000000669] [PMID: 25569009]
[98]
Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017; 8: CD008587
[http://dx.doi.org/10.1002/14651858.CD008587.pub2] [PMID: 28796882]
[99]
Health Council of the Netherlands. Population screening for cervical cancer The Hague: Health Council of the Netherlands . 2011. publication no. 2011/07E. ISBN 978-90-5549-866-6.
[100]
Medical Services Advisory Committee of Australia. Australia MSAC application No 1276 . National Cervical Screening Program Renewal 2013.
[101]
Smith MA, Gertig D, Hall M, et al. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Serv Res 2016; 16: 147.
[http://dx.doi.org/10.1186/s12913-016-1375-9] [PMID: 27112193]
[102]
Di Stefano F, Giorgi Rossi P, Carozzi F, et al. Gruppo di lavoro MIDDIR - HPV test in primary screening. [Implementation of DNA-HPV primary screening in Italian cervical cancer screening programmes. Results of the MIDDIR Project]. Epidemiol Prev 2017; 41(2): 116-24.
[PMID: 28627153]
[103]
Integrating HPV testing in cervical cancer screening program: a manual for program managers. Washington, D.C.: PAHO. 2016.Available from: https://www.paho.org/hq/ dmdocuments/ 2016/manual
[104]
Medscape. Boardman CH, Matthews KJ. Eds. Huh WK. Cervical Cancer Guidelines. Available from:. http://emedicine.medscape.com/article/253513-guidelines
[105]
Basu P, Mittal S, Bhadra Vale D, Chami Kharaji Y. Secondary prevention of cervical cancer. Best Pract Res Clin Obstet Gynaecol 2018; 47: 73-85.
[http://dx.doi.org/10.1016/j.bpobgyn.2017.08.012] [PMID: 28988647]
[106]
Mittal S, Mandal R, Banerjee D, et al. HPV detection-based cervical cancer screening program in low-resource setting: lessons learnt from a community-based demonstration project in India. Cancer Causes Control 2016; 27(3): 351-8.
[http://dx.doi.org/10.1007/s10552-015-0708-z] [PMID: 26712612]
[107]
Ghosh I, Mittal S, Banerjee D, et al. Study of accuracy of colposcopy in VIA and HPV detection-based cervical cancer screening program. Aust N Z J Obstet Gynaecol 2014; 54(6): 570-5.
[http://dx.doi.org/10.1111/ajo.12282] [PMID: 25476810]
[108]
Adsul P, Manjunath N, Srinivas V, Arun A, Madhivanan P. Implementing community-based cervical cancer screening programs using visual inspection with acetic acid in India: A systematic review. Cancer Epidemiol 2017; 49: 161-74.
[http://dx.doi.org/10.1016/j.canep.2017.06.008] [PMID: 28704717]
[109]
Tao L, Amanguli A, Li F, et al. Cervical Screening by Pap Test and Visual Inspection Enabling Same-Day Biopsy in Low-Resource, High-Risk Communities. Obstet Gynecol 2018; 132(6): 1421-9.
[http://dx.doi.org/10.1097/AOG.0000000000002973] [PMID: 30399093]
[110]
Screening and treatment of cervical pre-cancer. Chapter 5. In: Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd ed. Geneva: World Health Organization;. 2014.Available from: https://www.ncbi.nlm.nih.gov/books/NBK269608/
[111]
Nedjai B, Reuter C, Hollingworth T, et al. Non-invasive methylation test to detect cervical pre-cancer in self-collected vaginal and urine specimens. Available from: Abstracts from the NCRI Cancer Conferences. 2019.Abstract 2451 Available from: https://abstracts.ncri.org.uk/abstract/non-invasive-methylation-test-to-detect-cervical-pre-cancer-in-self-collected-vaginal-and-urine-specimens/
[112]
Human Development Reports. 2018.Available from: https://www.hdr.undp.org
[113]
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v11: Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11. Lyon, France: International Agency for Research on Cancer. 2014.http://globocan.iarc.fr
[114]
Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Kazakhstan. Summary Report . 23 Dec 2015.Available from: www.hpvcentre.net/statistics/ reports/KAZ
[115]
World Health Organization. Cancer Country Profile Available from: https://www.who.int/cancer/country-profiles.../
[116]
Aimagambetova G, Azizan A. Epidemiology of HPV Infection and HPV-Related Cancers in Kazakhstan: a Review. Asian Pac J Cancer Prev 2018; 19(5): 1175-80.
[PMID: 29801397]
[117]
Niyazmetova L, Aimagambetova G, Stambekova N, et al. Application of molecular genotyping to determine prevalence of HPV strains in Pap smears of Kazakhstan women. Int J Infect Dis 2017; 54: 85-8.
[http://dx.doi.org/10.1016/j.ijid.2016.11.410] [PMID: 27894986]
[118]
Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128(4): 927-35.
[http://dx.doi.org/10.1002/ijc.25396] [PMID: 20473886]
[119]
Bekmukhambetov YZ, Mynbaev OA, Tinelli A, et al. Human Papillomavirus related issues in western Kazakhstan: Protocol for a comprehensive study. Rus Open Med J 2018; 7(4): e0408
[http://dx.doi.org/10.15275/rusomj.2018.0408]
[120]
Balmagambetova S, Gabutti G, Koyshybaev A, et al. Cervical screening in Western Kazakhstan: Liquid-based cytology ‘Cell Scan’ versus azur-eosin staining. J Med Screen 2019; 969141319885409
[http://dx.doi.org/10.1177/0969141319885409] [PMID: 31744375]
[121]
Kaidarova D, Zhylkaidarova A, Dushimova Z, Bolatbekova R. Screening for Cervical Cancer in Kazakhstan JGO Sep 28, 2018.Available from: https://ascopubs.org/doi/abs/10.1200/jgo.18.65600
[http://dx.doi.org/10.1200/jgo.18.65600]
[122]
Sadovsky AD, Poton WL, Reis-Santos B, Barcelos MR, Silva IC. [Human Development Index and secondary prevention of breast and cervical cancer: an ecological study]. Cad Saude Publica 2015; 31(7): 1539-50.
[http://dx.doi.org/10.1590/0102-311X00073014] [PMID: 26248108]
[123]
Balmagambetova S, Koyshybaev A, Sakiyeva K, et al. Results of a survey concerning cervical cancer risk factors among women of western Kazakhstan. In: Infectious Diseases Current Perspectives in Human Papillomavirus . London: IntechOpen . 2018; 2: : pp. 111-35.
[124]
Karamanidou C, Dimopoulos K. Greek health professionals’ perceptions of the HPV vaccine, state policy recommendations and their own role with regards to communication of relevant health information. BMC Public Health 2016; 16(467): 467.
[http://dx.doi.org/10.1186/s12889-016-2831-5] [PMID: 27260348]
[125]
Igissinov N, Zatoskikh V, Moore MA, et al. Laryngeal cancer in Kazakhstan - ethnic, age and gender differences over time. Asian Pac J Cancer Prev 2013; 14(11): 7033-8.
[http://dx.doi.org/10.7314/APJCP.2013.14.11.7033] [PMID: 24377645]
[126]
Onerci Celebi O, Sener E, Hosal S, Cengiz M, Gullu I, Guler Tezel G. Human papillomavirus infection in patients with laryngeal carcinoma. BMC Cancer 2018; 18(1): 1005.
[http://dx.doi.org/10.1186/s12885-018-4890-8] [PMID: 30342481]
[127]
Torrente MC, Rodrigo JP, Haigentz M Jr, et al. Human papillomavirus infections in laryngeal cancer. Head Neck 2011; 33(4): 581-6.
[http://dx.doi.org/10.1002/hed.21421] [PMID: 20848441]
[128]
Adilbayev G, Kydyrbayeva G, Shipilova V, Sadyk Z, Adilbay D. Immediate results HPV-induced cancer of the mouth and oropharynx in Kazakhstan. Ann Oncol 2016; 27: 1.
[http://dx.doi.org/10.1093/annonc/mdw587.022]
[129]
Adilbay D, Adilbayev G, Kidirbayeva G, et al. HPV infection and P16 expression in oral and oropharyngeal cancer in Kazakhstan. Infect Agent Cancer 2018; 13: 2.
[http://dx.doi.org/10.1186/s13027-018-0175-8] [PMID: 29344081]
[130]
Bruni L, Albero G, Serrano B, Mena M, et al. ICO Information Centre on HPV and cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Kazakhstan. Summary Report. 17 June 2019. Available from: www.hpvcentre.net/ statistics/reports/KAZ

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy